Volociximab

Template:Drugbox-mab

Volociximab (also known as M200) is a chimeric monoclonal antibody jointly developed by PDL BioPharma and Biogen Idec for treatment of a variety of advanced solid tumors. It binds to and inhibits the functional activity of α5β1 integrin.

• Official website

Template:Chimericmonoclonals Template:WH Template:WikiDoc Sources